Tags

Type your tag names separated by a space and hit enter

Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Oncotarget 2016; 7(39):64410-64420O

Abstract

Although the Ventana immunohistochemistry (IHC) platform for detecting anaplastic lymphoma kinase gene (ALK) (D5F3) expression was recently approved by the US Food and Drugs Administration (FDA), fluorescence in situ hybridization (FISH) is still the "gold-standard" method recommended by the US National Comprehensive Cancer Network (NCCN) guideline for NSCLC. We evaluated 6 ALK-positive lung adenocarcinoma patients who tested Ventana IHC-positive and FISH-negative and assessed their clinical responses to the ALK tyrosine kinase inhibitor (TKI) crizotinib. Histologic and cytologic specimens from the 6 patients were stained with Ventana anti-ALK(D5F3) rabbit monoclonal primary antibody using the OptiView™ DAB IHC detection kit and OptiView™ amplification kit on a Ventana BenchMark XT processor. In addition, they were also tested by FISH, qRT-PCR, next-generation sequencing (NGS), and RNAscope ISH analysis. All patients received crizotinib treatment and their follow-up clinical data were recorded. The objective response rate achieved with crizotinib therapy was 66.7% (4/6 partial responses and 2/6 stable disease). One patient in whom a new fusion type (EML4->EXOC6B->ALK fusion) was identified obtained a partial response. These findings indicate that patients with ALK-positive lung adenocarcinoma who test Ventana IHC-positive and FISH-negative may still respond to crizotinib therapy.

Authors+Show Affiliations

Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, China.Department of Pathology, Beijing Hospital of the Ministry of Health, Beijing, China.Department of Pathology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, China.Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, China.Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, China.Department of Diagnostic Radiology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, China.Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, China.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China.

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

27418132

Citation

Ma, Di, et al. "Responses to Crizotinib in Patients With ALK-positive Lung Adenocarcinoma Who Tested Immunohistochemistry (IHC)-positive and Fluorescence in Situ Hybridization (FISH)-negative." Oncotarget, vol. 7, no. 39, 2016, pp. 64410-64420.
Ma D, Wang Z, Yang L, et al. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative. Oncotarget. 2016;7(39):64410-64420.
Ma, D., Wang, Z., Yang, L., Mu, X., Wang, Y., Zhao, X., ... Lin, D. (2016). Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative. Oncotarget, 7(39), pp. 64410-64420. doi:10.18632/oncotarget.10560.
Ma D, et al. Responses to Crizotinib in Patients With ALK-positive Lung Adenocarcinoma Who Tested Immunohistochemistry (IHC)-positive and Fluorescence in Situ Hybridization (FISH)-negative. Oncotarget. 2016 Sep 27;7(39):64410-64420. PubMed PMID: 27418132.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative. AU - Ma,Di, AU - Wang,Zheng, AU - Yang,Lin, AU - Mu,Xinlin, AU - Wang,Yan, AU - Zhao,Xinming, AU - Li,Junling, AU - Lin,Dongmei, PY - 2015/09/21/received PY - 2016/06/29/accepted PY - 2016/7/16/pubmed PY - 2018/2/7/medline PY - 2016/7/16/entrez KW - ALK status KW - crizotinib KW - fluorescence in situ hybridization KW - immunohistochemistry KW - non-small-cell lung cancer SP - 64410 EP - 64420 JF - Oncotarget JO - Oncotarget VL - 7 IS - 39 N2 - Although the Ventana immunohistochemistry (IHC) platform for detecting anaplastic lymphoma kinase gene (ALK) (D5F3) expression was recently approved by the US Food and Drugs Administration (FDA), fluorescence in situ hybridization (FISH) is still the "gold-standard" method recommended by the US National Comprehensive Cancer Network (NCCN) guideline for NSCLC. We evaluated 6 ALK-positive lung adenocarcinoma patients who tested Ventana IHC-positive and FISH-negative and assessed their clinical responses to the ALK tyrosine kinase inhibitor (TKI) crizotinib. Histologic and cytologic specimens from the 6 patients were stained with Ventana anti-ALK(D5F3) rabbit monoclonal primary antibody using the OptiView™ DAB IHC detection kit and OptiView™ amplification kit on a Ventana BenchMark XT processor. In addition, they were also tested by FISH, qRT-PCR, next-generation sequencing (NGS), and RNAscope ISH analysis. All patients received crizotinib treatment and their follow-up clinical data were recorded. The objective response rate achieved with crizotinib therapy was 66.7% (4/6 partial responses and 2/6 stable disease). One patient in whom a new fusion type (EML4->EXOC6B->ALK fusion) was identified obtained a partial response. These findings indicate that patients with ALK-positive lung adenocarcinoma who test Ventana IHC-positive and FISH-negative may still respond to crizotinib therapy. SN - 1949-2553 UR - https://www.unboundmedicine.com/medline/citation/27418132/Responses_to_crizotinib_in_patients_with_ALK_positive_lung_adenocarcinoma_who_tested_immunohistochemistry__IHC__positive_and_fluorescence_in_situ_hybridization__FISH__negative_ L2 - http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=10560 DB - PRIME DP - Unbound Medicine ER -